Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

70.19 +1.44 (+2.10%)
Streaming Delayed Price Updated: 2:04 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
47 48 Next >
Australia's Central Bank Has Raised Its Interest Rate. Business Activity In Europe Is Falling
Australia's Central Bank raised its interest rate by 50 basis points to 1.85%. The Bank said in a statement that it attaches great importance to getting inflation back into the 2-3 percent range over... 
Via Talk Markets
Recap Of Thursday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Gilead's Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients
Via Benzinga
Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
From Gilead Sciences, Inc.
Via Business Wire
European Commission Signs COVID-19 Drug Procurement Deal With Gilead
Via Benzinga
Daily Stock Analysis: Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. 
Via Talk Markets
Expert Ratings for Gilead Sciences
Analysts have provided the following ratings for Gilead Sciences (NASDAQ:GILD) within the last quarter: 
Via Benzinga
8 Dividend ETFs to Buy and Hold Forever
Dividend ETFs like these eight provide investors with a steady source of income while they wait for the stock market to recover. 
Via InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
Why NuCana Shares Are Rising Today?
Via Benzinga
CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
From Gilead Sciences, Inc.
Via Business Wire
7 Best Pharmaceutical Stocks to Buy Now
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
From Gilead Sciences, Inc.
Via Business Wire
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Gilead Sciences Whale Trades For July 14
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.03% on an annualized basis producing an average annual return of 15.0%. Currently, Gilead Sciences has a market... 
Via Benzinga
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Gilead Sciences, Inc.
Via Business Wire
Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?
When you're on the hunt for a great long-term dividend stock, you may want the perfect stock. The Dividend Aristocrats or Dividend Kings may come to mind first — companies that have proven they offer a... 
Via MarketBeat
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
Upgrades 
Via Benzinga
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
From Gilead Sciences, Inc.
Via Business Wire
Liposome Drug Delivery Market Size, Share, Key Players Analysis, Growth Factors, New Technology, Application and Regional Forecast to 2028
Global Liposome Drug Delivery Market Size was estimated at USD 3316.64 million in 2021 and is projected to reach USD 7768.01 million by 2028, exhibiting a CAGR of 12.93% during the forecast period 
Via SBWire
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
Q2 Earnings: Energy and What Else?
S&P 500 earnings are expected to be up 2.5% year-over-year on 10.8% higher revenues. But much of that is attributed to energy, which is expected to have another record quarter. 
Via Talk Markets
AstraZeneca's COVID-19 Treatment Allowed In China's Southern City: Reuters
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.